Novanta Inc
Research Novanta Inc (NOVT) on Bullrun: valuation model: 26.6% overvalued, market cap USD 5.28B, P/E 89.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNOVT
- ExchangeNASDAQ
- CountryUnited States
- SectorTechnology
- IndustryScientific & Technical Instruments
- CurrencyUSD
- Valuation signal26.6% overvalued
- Market capUSD 5.28B
- P/E89.3
- Financial periodQ2 2026
- RevenueUSD 257.71M
- Net incomeUSD 21.10M
- Free cash flowUSD 47.47M
- Gross margin44.1%
Valuation Snapshot
Bullrun's latest valuation model marks Novanta Inc as 26.6% overvalued; latest market cap is USD 5.28B; P/E is 89.3.
Peer valuation comparison
Latest P/E is 89.26x versus a Technology sector median of 28.57x (212.4% above).
Latest P/E is 89.26x versus a United States median of 24.87x (258.9% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 980.60M | USD 53.83M | USD 48.43M | 44.4% | 1.47 | USD 380.87M | USD 250.83M | USD 1.31B |
| FY2024 | USD 949.25M | USD 64.09M | USD 141.35M | 44.4% | 1.77 | USD 113.99M | USD 416.64M | USD 745.70M |
| FY2023 | USD 881.66M | USD 72.88M | USD 100.11M | 45.4% | 2.02 | USD 105.05M | USD 354.37M | USD 673.46M |
| FY2022 | USD 860.90M | USD 74.05M | USD 71.14M | 44.0% | 2.06 | USD 100.11M | USD 435.46M | USD 577.59M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 5.28B | 89.3 | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.24B | 81.5 | n/a | n/a |
| 2024 | 2024-12-31 | USD 5.49B | 86.3 | n/a | n/a |
| 2023 | 2023-12-29 | USD 6.03B | 80.2 | n/a | n/a |
| 2022 | 2022-12-30 | USD 4.85B | 67.3 | n/a | n/a |
| 2021 | 2021-12-31 | USD 6.28B | 125.1 | n/a | n/a |
About Novanta Inc
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments.
Related stock research
Other Technology stocks
Frequently asked questions
Is Novanta Inc overvalued or undervalued?
Bullrun's valuation model currently marks Novanta Inc as 26.6% overvalued.
What is Novanta Inc's market cap?
Novanta Inc's market capitalization is USD 5.28B.
What is Novanta Inc's P/E ratio?
Novanta Inc's price-to-earnings (P/E) ratio is 89.3.
What does Novanta Inc do?
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles.